Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|June 29, 2017
Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
Advertisement
Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.
There are several clinical trials investigating the sequencing of targeted therapies, explains Ascierto. There is a particular trial looking at the sequencing of the encorafenib and binimetinib combination, nivolumab (Opdivo) and ipilimumab (Yeroy) combination, and a third arm of immunotherapy in between targeted therapy agents.
<<<
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
3
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5